Company / Net Income
SAB Biotherapeutics, Inc. Net Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$34.1M
FY2025
5-year range
-$42.2M / $20.1M
FY2021-FY2025
Trend
+19.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income returned to growth in FY2025 after 3 years of decline, reaching -$34M.
Based on SEC 10-K filings.
-$34M in FY2025.
Declined from -$19M to -$34M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 19.2% year-over-year.
- Peak net income was recorded in FY2021.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$34.1M | +19.2% |
| FY2024 | -$42.2M | -125.1% |
| FY2023 | -$18.7M | -9.3% |
| FY2022 | -$17.1M | -185.2% |
| FY2021 | $20.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026